NCT02511405

A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)

A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 252 (estimated)
• Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
DRUG	VB-111 + bevacizumab	VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
DRUG	Bevacizumab	Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks

Timeline

• Start date: 2015-08-01
• Primary completion: 2017-11-03
• Completion: 2018-09-30
• First posted: 2015-07-30
• Last updated: 2018-10-23

Locations

57 sites across 3 countries: United States, Canada, Israel